Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Inventory (2016 - 2025)

Historic Inventory for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $185.9 million.

  • Amphastar Pharmaceuticals' Inventory rose 4267.78% to $185.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.9 million, marking a year-over-year increase of 4267.78%. This contributed to the annual value of $153.7 million for FY2024, which is 4526.75% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Inventory is $185.9 million, which was up 4267.78% from $191.7 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Inventory high stood at $191.7 million for Q2 2025, and its period low was $92.8 million during Q4 2021.
  • In the last 5 years, Amphastar Pharmaceuticals' Inventory had a median value of $104.6 million in 2023 and averaged $120.9 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Inventory crashed by 1000.0% in 2021, and later surged by 6059.36% in 2025.
  • Amphastar Pharmaceuticals' Inventory (Quarter) stood at $92.8 million in 2021, then increased by 11.61% to $103.6 million in 2022, then grew by 2.17% to $105.8 million in 2023, then surged by 45.27% to $153.7 million in 2024, then rose by 20.94% to $185.9 million in 2025.
  • Its last three reported values are $185.9 million in Q3 2025, $191.7 million for Q2 2025, and $185.5 million during Q1 2025.